Results 31 to 40 of about 17,282 (226)
Рациональная фармакотерапия в кардиологии, 2016 Aim. To evaluate the heart rate variability (HRV) in patients with ischemic heart disease (IHD) and paroxysmal atrial fibrillation (AF) during atorvastatin therapy.Material and methods.
E. S. Kozlova +3 more
doaj +1 more source
Rate-Control or Rhythm-Contol: Where do we stand? [PDF]
, 2005 Atrial fibrillation is the most common sustained rhythm disturbance and its prevalence is increasing worldwide due to the progressive aging of the population.
A, Dello Russo +6 more
core +1 more source
Endothelin and the ischaemic heart [PDF]
, 2005 Soon after its identification as a powerful vasoconstrictor peptide, endothelin (ET-1) was implicated as a detrimental agent involved in determining the outcome of myocardial ischaemia and reperfusion.
Kane, K.A., McCabe, C., Wainwright, C.L.
core +1 more source
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT Autosomal recessive loss‐of‐function variants in PPP1R13L cause an ultra‐rare cardiocutaneous syndrome characterized by rapidly progressive arrhythmogenic cardiomyopathy (ACM). PPP1R13L encodes iASPP, which has two potentially overlapping mechanisms driving ACM as both a regulator of NFκB‐mediated inflammation and a binding partner within the ...
Aaron Renberg +9 more
wiley +1 more source
Micro-RNA family that modulates fibrosis and uses thereof [PDF]
, 2017 The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response
Olson, Eric N., van Rooij, Eva
core +1 more source
American Journal of Medical Genetics Part A, EarlyView.ABSTRACT Arrhythmias affect approximately half of patients with Costello syndrome (CS, OMIM # 218040), with non‐reentrant atrial tachycardia being the most common. This case describes an infant with Costello syndrome carrying the pathogenic HRAS c.34G>A (p.G12S) variant who developed early‐onset, drug‐refractory multifocal atrial tachycardia (MAT ...
Vanina Taliercio +11 more
wiley +1 more source
Safety issues of antiarrhythmic therapy for atrial fibrillation
Клинический разбор в общей медицинеThe article discusses the safety of antiarrhythmic therapy for atrial fibrillation in the light of the development of cardiac and non-cardiac side effects, the presence of drug-drug interactions of antiarrhythmic drugs in the near (with anticoagulants ...
I.I. Reznik , Ya.G. Bozhko
doaj +1 more source
Future evaluation of antiarrhythmic therapy
American Heart Journal, 1994 The expansion of antiarrhythmic therapy beyond pharmacologic agents to include surgery, devices, and ablation procedures, plus the reaffirmation by the Cardiac Arrhythmia Suppression Trial (CAST) of the need for concurrent placebo-controlled trials to establish a mortality benefit, have resulted in the need to consider the requirements for evaluating ...
R J, Myerburg +6 more
openaire +2 more sources
Role of pharmacotherapy in Brugada syndrome [PDF]
, 2004 In patients who undergo aborted sudden cardiac death or syncope of unknown origin (symptomatic Brugada syndrome), no one argues that the implantation of an ICD is the first-line therapy regardless of the findings of the EP study.
Tsuchiya, Takeshi
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga +20 more
wiley +1 more source